Apparatus, system, and method for generating photo-biologic minimum biofilm inhibitory concentration of infrared light
AssigneeNomir Medical Technologies, Inc.
InventorEric Bornstein
Life of this patent
Estimating the term…
Abstract
Systems and methods are disclosed herein for prophylactic application of near-infrared optical energies and dosimetries to photo-biologically inhibit accelerations or intensifications in biofilm production, after a bacterial or fungal pathogen is challenged with an antibiotic or antifungal agent. This photo-biologic minimum biofilm inhibitory concentration (PMBIC) of infrared light will lower the minimum inhibitory concentration (MIC) necessary of an antibiotic and/or antifungal molecule necessary to decrease bacterial and fungal pathogens in human tissues. These systems and methods will only target undesirable microbial cells.
Claims4
A method for inhibiting biofilm production in Methicillin-resistant Staphylococcus aureus (MRSA) colonies in a human nasal cavity, the method comprising:
- applying, through a diffuser tip configured to generate a uniform cylindrical energy projection, treatment light to a treatment site in the nasal cavity in a manner configured to reduce a mutant prevention concentration for biofilm-producing MRSA in which:
- the treatment light comprises light with a first wavelength of about 870 nm and a second wavelength of about 930 nm;
- the treatment light is applied at a dosimetry comprising a power density of about 0.5 W/cm2 to 0.75 W/cm2 and an energy density of about 200 J/cm2 to 400 J/cm2 for a duration of about 300 seconds to 500 seconds per nostril;
- and
- the applied treatment light has a flat-top energy profile and is delivered in a continuous wave over the duration of application;
- and
- applying a Mupirocin formulation to the treatment site after or concurrently with applying the treatment light such that a concentration of Mupirocin that reaches the treatment site is greater than the mutant prevention concentration for biofilm-producing MRSA.
A method for inhibiting biofilm production in Methicillin-resistant Staphylococcus aureus (MRSA) colonies in a diabetic foot wound of a subject, the method comprising:
- applying, through an optical radiation delivery assembly configured to generate a uniform energy projection, treatment light to a treatment site in the diabetic foot wound in a manner configured to reduce a mutant prevention concentration for biofilm-producing MRSA in which:
- the treatment light comprises light with a first wavelength of about 870 nm and a second wavelength of about 930 nm;
- the treatment light is applied to the foot wound at a dosimetry comprising a power density of about 0.5 W/cm2 to 0.75 W/cm2 and an energy density of about 200 J/cm2 to 400 J/cm2 for a duration of about 300 seconds to 500 seconds;
- and
- the applied treatment light has a flat-top energy profile and is delivered in a continuous wave over the duration of application;
- and
- administering a Doxycycline formulation to the subject after or concurrently with applying the treatment light such that a concentration of Doxycycline that reaches the treatment site is greater than the mutant prevention concentration for biofilm-producing MRSA.
A method for preventing phenotypic upregulation of biofilm formation in Methicillin-resistant Staphylococcus aureus (MRSA) in a human nasal cavity during decolonization therapy, the method comprising:
- applying, through a diffuser tip configured to generate a uniform cylindrical energy projection, treatment light to a treatment site in the nasal cavity in a manner configured to reduce a mutant prevention concentration for biofilm-producing MRSA in which:
- the treatment light comprises light with a first wavelength of about 870 nm and a second wavelength of about 930 nm;
- the treatment light is applied at a dosimetry comprising a power density of about 0.5 W/cm2 to 0.75 W/cm2 and an energy density of about 200 J/cm2 to 400 J/cm2 for a duration of about 300 seconds to 500 seconds per nostril;
- and
- the applied treatment light has a flat-top energy profile and is delivered in a continuous wave over the duration of application;
- and
- applying a topical Mupirocin formulation to the treatment site after or concurrently with applying the treatment light such that a concentration of Mupirocin that reaches the treatment site is greater than the mutant prevention concentration for biofilm-producing MRSA.
A method for preventing phenotypic upregulation of biofilm formation in Methicillin-resistant Staphylococcus aureus (MRSA) in a diabetic foot wound during decolonization therapy, the method comprising:
- applying, through an optical radiation delivery assembly configured to generate a uniform energy projection, treatment light to a treatment site in the diabetic foot wound in a manner configured to reduce a mutant prevention concentration for biofilm-producing MRSA in which:
- the treatment light comprises light with a first wavelength of about 870 nm and a second wavelength of about 930 nm;
- the treatment light is applied to the foot wound at a dosimetry comprising a power density of about 0.5 W/cm2 to 0.75 W/cm2 and an energy density of about 200 J/cm2 to 400 J/cm2 for a duration of about 300 seconds to 500 seconds;
- and
- the applied treatment light has a flat-top energy profile and is delivered in a continuous wave over the duration of application;
- and
- applying a Doxycycline formulation to the application region after or concurrently with applying the treatment light such that a concentration of Doxycycline that reaches the treatment site is greater than the mutant prevention concentration for biofilm-producing MRSA.
Dependencies are inferred from the claim text.